-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from 2021 to 2023.
- Inhibikase Therapeutics, Inc. Depreciation for the quarter ending September 30, 2024 was $6.57K, unchanged year-over-year.
- Inhibikase Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2024 was $26.3K, a 85.1% decline year-over-year.
- Inhibikase Therapeutics, Inc. annual Depreciation for 2023 was $177K, a 2539% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Depreciation for 2022 was $6.72K.
Depreciation, Trailing 12 Months (USD)
Depreciation, Annual (USD)
Depreciation, YoY Annual Growth (%)